In the UK, current rates of CKD screening, coding and guideline-directed prescribing are low in primary care; earlier identification and treatment could save thousands of lives*⁴

* Modelling by Kidney Research UK suggestions that improved screening/diagnosis, management, use of SGLT2is and transplant rates could save >10,000 lives between 2023 and 2033.⁴

Elevated UACR or reduced eGFR is independently associated with a higher risk of CKD progression and CV death^5,6

KDIGO and ADA guidelines recommend 2 tests (UACR and eGFR) annually in at-risk individuals as early as possible to adequately assess for kidney damage.⁷

The KDIGO heat map is a useful tool to provide guidance on monitoring and treatment in people with CKD

Access the KDIGO digital heatmap tool to understand the cardiovascular and renal risk associated with the CKD stage of your patient.

KDIGO digital heatmap

The above tool was developed by Boehringer Ingelheim in collaboration with KDIGO.

*
The trial enrolled 6,609 patients who had evidence of CKD at risk of kidney disease progression, with and without diabetes, with and without albuminuria. Patients with an eGFR ≥20 to <45 mL/min/1.73m², or an eGFR ≥45 to <90 mL/ min/1.73m² with a UACR ≥200mg/g, were randomised to receive either 10mg empagliflozin (n=3304) or placebo (n=3305) on top of standard of care. JARDIANCE® achieved primary endpoint vs placebo: risk reduction in kidney disease progression or CV death 28% RRR/3.6% ARR (HR=0.72; 95% CI: 0.64, 0.82; p<0.001). Kidney disease progression was defined as end-stage kidney disease (ESKD: the initiation of maintenance dialysis or receipt of a kidney transplant), a sustained decrease in the eGFR to <10 mL/min/1.73m² , a sustained decrease from baseline in the eGFR of at least 40%, or death from renal causes.^9,10

EMPA-KIDNEY included the broadest range of patients amongst the SGLT2i CKD RCTs in terms of eGFR and those with and without albuminuria^9,11,12

Inclusion criteria of the SGLT2i CKD trials mapped to KDIGO guidance

NICE 2023 TA942 recommendation for the use of empagliflozin in adults with CKD when mapped to the KDIGO 2024 guidance on CKD prognosis by eGFR and albuminuria categories. It is recommended as an add-on to optimised standard care including the highest tolerated licensed dose of ACE inhibitors or ARBs, unless these are contraindicated.¹⁴

EARLY intervention with JARDIANCE® may help patients avoid dialysis for longer¹⁵

Potential impact on time to dialysis versus SoC based on extrapolated data from the EMPA-KIDNEY trial

Based on hypothetical transformation of chronic eGFR slopes into time to kidney failure, i.e., time to need for kidney replacement therapy, defined as  eGFR = 10mL/min/1.73m². Data estimated from each baseline eGFR value by applying the chronic eGFR slopes corresponding to participants on standard of care vs empagliflozin within the prespecified eGFR subgroups (eGFR cutoff points to define subgroups).

Latest resource

Webinar - 5 minute highlight - BEYOND THE FILTER

Watch Professor Smeeta Sinha and Dr Sarah Jarvis explore the role of SGLT2 inhibitors in CKD management—as they discuss the burden of CKD, current treatment approaches including uACR testing, key insights from the EMPA-KIDNEY trial, and prescribing considerations for empagliflozin.

Expand your learning

JARDIANCE® (empagliflozin) T2D, CKD, HF patient booklets

JARDIANCE® (empagliflozin) initiation and management guide

Download now Opens in new tab

JARDIANCE® (empagliflozin) patient booklet

Download now Opens in new tab

Abbreviations

ADA: American Diabetes Association; ARR: absolute risk reduction; CI: confidence interval; CRM: cardio renal metabolism; CV: cardiovascular; CVD: cardiovascular disease; HR: hazard ratio; KDIGO: Kidney Disease: Improving Global Outcomes; MACE: major adverse cardiovascular events; MI: myocardial infarction; NICE: National Institute for Health and Care Excellence; PAD: peripheral artery disease; QOF: quality and outcomes framework; RCT: randomised controlled trial; RRR: relative risk reduction; SGLT2: sodium-glucose co-transporter-2; SGLT2i: sodium-glucose co-transporter-2 inhibitor; SoC: standard of care; UKKA: UK Kidney Association.

GBD Chronic Kidney Disease Collaboration. Lancet. 2020;395(10225):709–733.
Jankowski J, et al. Circulation. 2021;143(11):1157–1172.
Borg R, et al. Int J Nephrol. 2023 Mar
Kidney Research UK. Kidney disease: a UK public health emergency. The health economics of kidney disease to 2033. 2023. Available at: https://www.kidneyresearchuk.org/wp-content/uploads/2023/06/Economics-of-Kidney-Disease-full-report_accessible.pdf.
Choi Y et al. J Am Heart Assoc. 2022;11:e026685.
van der velde M et al. Kidney International. (2011);79:1341–1352.
de Boer IH, et al. Diabetes Care. 2022;45(12):3075–3090.
JARDIANCE (empagliflozin) Summary of Product Characteristics (SmPC).
Herrington WG, et al. N Engl J Med. 2023;388(2):117-127. (EMPA-KIDNEY results and the publication’s Supplementary Appendix).
JARDIANCE Data on File (EMP 23-22).
Heerspink HJL et al. N Engl J Med. 2020;383:1436–1446.
Perkovic V et al. N Engl J Med. 2019;380:2295–2306.
Kidney Disease: Improving Global outcomes (KDIGO) CKD Work Group. Kidney Int.2024;105(4S):S117-S314.
NICE. Empagliflozin for treating chronic kidney disease: Technology appraisal guidance (TA942). 2023. Available from: https://www.nice.org.uk/guidance/ta942/.
Fernández-Fernandez B, Sarafidis P, Soler MJ, Ortiz A. Clin Kidney J. 2023;16(8):1187–1198.

PC-GB-111790 | August 2025

Reporting adverse events

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).

Please be aware that this website contains promotional information about Boehringer Ingelheim medicines and services. Some of this may not be directly relevant to your scope of practice and it is your own decision whether you choose to view this information.

Disclaimer

The content on this website is in relation to adult patients.

Empagliflozin is not recommended in severe hepatic impairment, breastfeeding, Type 1 diabetes and is contraindicated in patients with hypersensitivity to the active ingredient or any of its excipients. Empagliflozin should be avoided in pregnancy.

Please consult the SmPC for full details regarding adverse events, monitoring requirements and interactions prior to prescribing JARDIANCE®.

JARDIANCE® (empagliflozin) UK Summary of Product Characteristics (SmPC). Available at:
http://www.medicines.org.uk/emc/medicine/28973.

Indications

JARDIANCE® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise

as monotherapy when metformin is considered inappropriate due to intolerance
in addition to other medicinal products for the treatment of diabetes¹

JARDIANCE® is indicated in adults for the treatment of chronic kidney disease.¹

JARDIANCE® is indicated in adults for the treatment of symptomatic chronic heart failure.¹

PC-GB-109995 V4 | October 2025

Protect the Kidneys
of your patients living with CKD through early identification and
treatment

CKD is a PROGRESSIVE DISEASE and acts as a CV risk multiplier^1,2

In the UK, current rates of CKD screening, coding and guideline-directed prescribing are low in primary care; earlier identification and treatment could save thousands of lives*⁴

Elevated UACR or reduced eGFR is independently associated with a higher risk of CKD progression and CV death^5,6

The KDIGO heat map is a useful tool to provide guidance on monitoring and treatment in people with CKD

JARDIANCE® offers protection by reducing the risk of kidney disease progression or cardiovascular death in adult patients with CKD vs placebo, as demonstrated in EMPA-KIDNEY — the largest SGLT2i CKD RCT to date^8,9

EMPA-KIDNEY included the broadest range of patients amongst the SGLT2i CKD RCTs in terms of eGFR and those with and without albuminuria^9,11,12

EARLY intervention with JARDIANCE® may help patients avoid dialysis for longer¹⁵